NCT01495221View on ClinicalTrials.gov

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Interventions
DRUG

Alfilbercept

All patients will receive 2.0 mg intravitreal aflibercept injection.

Trial Locations (1)

10022

Vitreous Retina Macula Consultants of New York, New York

All Listed Sponsors
lead

Vitreous -Retina- Macula Consultants of New York

OTHER

NCT01495221 - To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD | Biotech Hunter | Biotech Hunter